Trial · NCT07537010
3D1015 Injection for Patients With mCRPC
NCT07537010, Phase 1, Recruiting, Chunjing Yu
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. 3D1015 Injection for Patients With mCRPC. Trials, record NCT07537010. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07537010
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- 3D1015 Injection for Patients With mCRPC
- NCT number
- NCT07537010
- Status
- Recruiting
- Phases
- Phase 1
- Enrollment
- 8 participants, estimated
- Lead sponsor
- Chunjing Yu
- Conditions
- Metastatic Castration-resistant Prostate Cancer, mCRPC
- Interventions
- Lu 177-PSMA-3D1015 Injection
- First posted
- 2026-04-17
- Last updated
- 2026-04-17
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence and severity of Treatment-Emergent Adverse Events (TEAEs) | From first dose of study drug through end of treatment (~36-48 weeks) | Safety and tolerability will be evaluated by monitoring the incidence and severity of TEAEs. |
| Primary | Occurrence of Dose-Limiting Toxicities (DLTs) | From first dose of study drug through end of treatment (~36-48 weeks) | Number of participants experiencing dose-limiting toxicities (DLTs) . |
| Primary | Absorbed Dose | From first dose of study drug through end of treatment (~36-48 weeks) | Absorbed dose to the whole body, critical organs (e.g., kidneys, salivary glands), and tumor lesions assessed via serial imaging data. |
| Primary | Effective Half-Life | From first dose of study drug through end of treatment (~36-48 weeks) | Effective half-life of the study drug in the whole body, major organs, and tumor lesions determined by serial imaging. |
| Secondary | The proportion of patients with a PSA change from baseline | From first dose of study drug through end of treatment (~36-48 weeks) | The effect of Lu 177-PSMA-3D1015 on prostate-specific antigen (PSA) kinetics. |
| Secondary | Objective Response Rate (ORR) | From first dose of study drug through efficacy follow-up period (Up to approximately 5 years) | Percentage of participants with a complete response (CR) or partial response (PR). |
| Secondary | Radiographic progression-free survival (rPFS) | From first dose of study drug through efficacy follow-up period (Up to approximately 5 years) | rPFS per investigator assessment. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07537010
GET https://conductscience.org/api/trials/v1/NCT07537010/registered